NCT07578116ClinicalTrials.gov
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy
In breve
This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with…
Fase 3562 partecipanti ricercati59 centri1 paese
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT07578116Apri questa scheda su ClinicalTrials.govSincronizzato mese scorso
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-05-11; recorded start 2027-03-09
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 72 other studies in this databaseCounted from the lead sponsor named in the record (SWOG Cancer Research Network)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 3 conditions.
- Lead sponsor type recorded as: research network.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A moderately rigorous design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 562 participants (target), run at 59 sites.
How this score is built
- Enrolment27/40
562 participants (target)
- Site count0/25
Site count not stated in the record
- Country count0/15
Country count not stated in the record
- Planned duration10/10
Planned over about 76 months
- Sponsor scale7/10
SWOG Cancer Research Network has led 72 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Adding locoregional therapy, as well as metastasis-directed SBRT, to standard systemic therapy may help patients with (oligo)metastatic, HER2-positive stage IV breast cancer live longer overall or before their cancer progresses, and may help more patients achieve no evidence of disease, when compared to standard systemic therapy alone.
Patologie
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic HER2-Positive Breast Carcinoma
- Oligometastatic Breast Carcinoma
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – Nessun massimo |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 3 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | NONE (0) |
| Arruolamento | 562 partecipanti ricercati |
Sponsor e collaboratori
- SWOG Cancer Research Network Sponsor
- National Cancer Institute (NCI) Collaboratori
Bracci e interventi
- Step 1 (HER2-targeted systemic therapy, STS/SRT)EXPERIMENTAL
Patients receive physician's choice of HER2-targeted systemic therapy according to NCCN/ASCO guidelines until completion of at least 12 weeks (4 cycles) or up to 24 weeks (8 cycles) of HER2-targeted therapy prior to Step 2 registration. Patients with brain metastases may also undergo SRS/SRT at the discretion of the treating physician. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.
- Step 2 Cohort A, Arm 1 (locoregional, SBRT, systemic therapy)EXPERIMENTAL
See Detailed Description.
- Step 2 Cohort A, Arm 2 (systemic therapy)EXPERIMENTAL
Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients may receive locoregional therapy and/or SBRT according to standard of care only if required for palliative purposes. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.
- Step 2 Cohort B (systemic therapy)EXPERIMENTAL
Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines in the absence of disease progression or unacceptable toxicity. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.
Interventi
- Procedura Biopsy Procedure
Undergo biopsy
- Procedura Biospecimen Collection
Undergo collection of blood samples
- Procedura Breast Conservation Treatment
Undergo breast conserving therapy
- Procedura Computed Tomography
Undergo CT and/or PET/CT
- Farmaco Cyclin-Dependent Kinase 4 Inhibitor
Given CDK4/6 inhibitor
- Farmaco Cyclin-Dependent Kinase 6 Inhibitor
Given CDK4/6 inhibitor
- Procedura Echocardiography Test
Undergo ECHO
- Farmaco HER2-targeted Therapy
Receive HER2-targeted systemic therapy
- Farmaco Hormone Therapy
Given endocrine therapy
- Procedura Magnetic Resonance Imaging
Undergo MRI
- Procedura Mammography
Undergo mammography
- Biologico Pertuzumab
Given pertuzumab
- Procedura Positron Emission Tomography
Undergo PET/CT
- Radiazioni Radiation Boost
Undergo RT boost
- Radiazioni Radiation Therapy
Undergo RT
- Radiazioni Stereotactic Body Radiation Therapy
Undergo SBRT
- Radiazioni Stereotactic Radiosurgery
Undergo SRS/SRT
- Farmaco Taxane Compound
Given taxane therapy
- Procedura Total Mastectomy
Undergo total mastectomy
- Biologico Trastuzumab
Given trastuzumab
- Biologico Trastuzumab Deruxtecan
Given T-DXd
- Biologico Trastuzumab Emtansine
Given T-DM1
- Procedura Ultrasound Imaging
Undergo ultrasound
Esiti misurati
Esito primario
Overall survival (OS) (Cohort A)
The primary analysis to evaluate the primary objective in the randomized cohort will be an intent-to treat (ITT) comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% confidence interval (CI) will be estimated by Cox regression including the stratification factors as variables in the model. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.
Orizzonte temporale From date of Step 2 registration to date of death, assessed up to 10 years
Esito primario
Progression-free survival (PFS) (Observational Cohort B)
In the observational cohort, the primary objective will be evaluated by estimating 3- and 5-year survival and corresponding 95% CIs using the Kaplan-Meier estimator. All analyses in the observational cohort will be descriptive. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.
Orizzonte temporale From date of Step 2 registration to date of first documentation of progression or recurrence or death, assessed at 3 and 5 years
Esito primario
Overall survival (Observational Cohort B)
In the observational cohort, the primary objective will be evaluated by estimating 3- and 5-year survival and corresponding 95% CIs using the Kaplan-Meier estimator. All analyses in the observational cohort will be descriptive. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.
Orizzonte temporale From date of Step 2 registration to date of death, assessed at 3 and 5 years
Esito secondario
Progression free survival (Cohort A)
The primary analysis will be an ITT comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% CI will be estimated by Cox regression including the stratification factors as variables in the model. In addition to the primary analyses, will estimate PFS at 3 years and 5 years in Arm 1 and Arm 2 and corresponding 95% CIs using the Kaplan-Meier estimator.
Orizzonte temporale From date of Step 2 registration to date of first documentation of progression or recurrence or death, assessed at 3 and 5 years and then up to 10 years
Esito secondario
Overall survival (Cohort A)
The primary analysis will be an ITT comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% CI will be estimated by Cox regression including the stratification factors as variables in the model. In addition to the primary analyses, will estimate OS at 3 years and 5 years in Arm 1 and Arm 2 and corresponding 95% CIs using the Kaplan-Meier estimator.
Orizzonte temporale From date of Step 2 registration to date of death, assessed at 3 and 5 years and then up to 10 years
Esito secondario
Duration of standard of care first line systemic therapy (Cohort B)
Orizzonte temporale From time of response assessment at end of Step 1 up to 10 years
Date
| Data di inizio | 9 marzo 2027 (stimata) |
|---|---|
| Conclusione primaria | 31 maggio 2032 (stimata) |
| Conclusione | 31 maggio 2033 (stimata) |
| Prima pubblicazione | 11 maggio 2026 (effettiva) |
| Ultimo aggiornamento | 13 ottobre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | ottobre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
59 centri stanno reclutando
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| OSF Saint Joseph Medical Center | Bloomington | Illinois | In reclutamento |
| Illinois CancerCare-Bloomington | Bloomington | Illinois | In reclutamento |
| Illinois CancerCare-Canton | Canton | Illinois | In reclutamento |
| Saint Francis Medical Center | Cape Girardeau | Missouri | In reclutamento |
| Illinois CancerCare-Carthage | Carthage | Illinois | In reclutamento |
| Mercy Cancer Center-West Lakes | Clive | Iowa | In reclutamento |
| Baptist Memorial Hospital and Cancer Center-Collierville | Collierville | Tennessee | In reclutamento |
| Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus | Mississippi | In reclutamento |
| Decatur Memorial Hospital | Decatur | Illinois | In reclutamento |
| Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois | In reclutamento |
| Smilow Cancer Hospital-Derby Care Center | Derby | Connecticut | In reclutamento |
| Mercy Medical Center - Des Moines | Des Moines | Iowa | In reclutamento |
| Iowa Methodist Medical Center | Des Moines | Iowa | In reclutamento |
| Broadlawns Medical Center | Des Moines | Iowa | In reclutamento |
| Illinois CancerCare-Eureka | Eureka | Illinois | In reclutamento |
| Smilow Cancer Hospital Care Center-Fairfield | Fairfield | Connecticut | In reclutamento |
| Illinois CancerCare-Galesburg | Galesburg | Illinois | In reclutamento |
| Smilow Cancer Hospital Care Center at Greenwich | Greenwich | Connecticut | In reclutamento |
| Baptist Cancer Center-Grenada | Grenada | Mississippi | In reclutamento |
| Smilow Cancer Hospital Care Center - Guilford | Guilford | Connecticut | In reclutamento |
| Smilow Cancer Hospital-Hamden Care Center | Hamden | Connecticut | In reclutamento |
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro | Arkansas | In reclutamento |
| Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois | In reclutamento |
| Illinois CancerCare-Macomb | Macomb | Illinois | In reclutamento |
| Bon Secours Memorial Regional Medical Center | Mechanicsville | Virginia | In reclutamento |
| Baptist Memorial Hospital and Cancer Center-Memphis | Memphis | Tennessee | In reclutamento |
| Bon Secours Saint Francis Medical Center | Midlothian | Virginia | In reclutamento |
| Baptist Memorial Hospital and Cancer Center-Union County | New Albany | Mississippi | In reclutamento |
| Smilow Cancer Center/Yale-New Haven Hospital | New Haven | Connecticut | In reclutamento |
| Yale University | New Haven | Connecticut | In reclutamento |
| Yale-New Haven Hospital North Haven Medical Center | North Haven | Connecticut | In reclutamento |
| Cancer Care Center of O'Fallon | O'Fallon | Illinois | In reclutamento |
| HSHS Saint Elizabeth's Hospital | O'Fallon | Illinois | In reclutamento |
| Orlando Health Cancer Institute | Orlando | Florida | In reclutamento |
| Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois | In reclutamento |
| Baptist Memorial Hospital and Cancer Center-Oxford | Oxford | Mississippi | In reclutamento |
| Illinois CancerCare-Pekin | Pekin | Illinois | In reclutamento |
| Illinois CancerCare-Peoria | Peoria | Illinois | In reclutamento |
| OSF Saint Francis Radiation Oncology at Peoria Cancer Center | Peoria | Illinois | In reclutamento |
| OSF Saint Francis Medical Center | Peoria | Illinois | In reclutamento |
| Illinois CancerCare-Peru | Peru | Illinois | In reclutamento |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | In reclutamento |
| Illinois CancerCare-Princeton | Princeton | Illinois | In reclutamento |
| Bon Secours Cancer Institute at Reynolds Crossing | Richmond | Virginia | In reclutamento |
| Bon Secours Saint Mary's Hospital | Richmond | Virginia | In reclutamento |
| Southern Illinois University School of Medicine | Springfield | Illinois | In reclutamento |
| Springfield Memorial Hospital | Springfield | Illinois | In reclutamento |
| Springfield Clinic | Springfield | Illinois | In reclutamento |
| Smilow Cancer Hospital Care Center at Long Ridge | Stamford | Connecticut | In reclutamento |
| Smilow Cancer Hospital-Torrington Care Center | Torrington | Connecticut | In reclutamento |
Nella scheda del registro sono indicati altri 9 centri.
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 13 ottobre 2026
Stato modificato
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 13 ottobre 2026
Reclutamento aperto
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 13 ottobre 2026
Centro aggiunto
59 sites added (59 total)
059